Accuracy High for Pathologists Interpreting Breast Biopsy. This study confirms that the majority of diagnoses, especially at either end of the spectrum from benign to invasive cancer, are readily and accurately made by practicing pathologists. 

Breast biopsies no longer reliable. New findings are challenging the common belief that a biopsy is the end-all answer to resolve any questions they might have about unclear mammograms. 

Doctors don't always agree on breast biopsies, and say women with aytpia or DCIS should seek second opinions. While doctors almost always agree on a pathological diagnosis of invasive breast cancer, there is room for improvement when diagnosing atypia (or atypical ductal hyperplasia-ADH) and DCIS (ductal carcinoma in-situ). 

Breast imaging providers must lead density education. In our breast imaging center, we have long made it a practice to have onsite reads of mammograms followed by in-person consultations with our patients. 

Advocating Breast Density. The push for additional screening is becoming prevalent, and many states are enacting laws that require women to be notified if they have dense breast tissue and what that means in terms of the ability to accurately find cancer. 

New Breast Density Technology Debuts at ECR Conference. A new research technology was profiled today during scientific sessions at the European Congress of Radiology (ECR) in Vienna, Austria. Densitas Research Edition assesses mammographic breast density using 'for presentation' digital mammography images. 

All Women Should Have Access To Ultrasound Screening For Breast Cancer. The optimal screening program should include ultrasound for women with dense breasts. The sound-wave test is good for detecting invasive cancers that are otherwise hard-to-spot in cloudy mammograms of dense breasts. 

Expanding on liquid biopsies with exosomes. A new type of liquid biopsy for solid tumors based on analyzing exosomes from the blood is being tested by clinicians. "The term 'liquid biopsy' describes the fact that a simple blood sample can contain many tumor-derived molecules and even tumor cells, enabling molecular analyses similar to those possible in tumor tissue samples. 

New imaging tool targets degenerative diseases. Researchers have developed the first imaging reagent that can determine thiol levels in intact living cells. Now they are working on reagents that can selectively show thiol density in subcellular structures, specifically the nucleus and mitochondria, hoping to develop a nontoxic reagent safe enough to be used for diagnostic imaging, like an MRI.